BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 193.38 |
| Open | 200.16 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 197.55 - 204.86 |
| 52 Week Range | 118.18 - 309.06 |
| Volume | |
| Avg. Volume | 271,280 |
| Market Cap | 20.853B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool
Why Shares of BeiGene Were Up Wednesday
Shares of Chinese pharmaceutical BeiGene (NASDAQ: BGNE) rose as high as 12.8% in early trading on Wednesday. BeiGene didn't make any big announcements, and its earnings report was back on Nov. 9, so the move was curious. Most likely, it was just a little bit of a return to normalcy after the stock took a beating when there were protests in China regarding the country's strict lockdown "zero tolerance" provisions regarding COVID-19.
- Simply Wall St.
In the wake of BeiGene, Ltd.'s (NASDAQ:BGNE) latest US$2.9b market cap drop, institutional owners may be forced to take severe actions
Every investor in BeiGene, Ltd. ( NASDAQ:BGNE ) should be aware of the most powerful shareholder groups. The group...
- Motley Fool
Is This Chinese Pharmaceutical Stock Worth the Risk?
BeiGene (NASDAQ: BGNE), is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing. It focuses on unique therapies to treat cancer, specializing in B-cell malignancies and solid tumors in lung and gastrointestinal cancers. Amid delisting concerns, a lot of Chinese stocks have fallen this year.
